Citigroup Cuts Abbott Laboratories (NYSE:ABT) Price Target to $140.00

Abbott Laboratories (NYSE:ABT) had its target price reduced by Citigroup from $155.00 to $140.00 in a report released on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the healthcare product maker’s stock. Citigroup’s price objective would indicate a potential upside of 30.63% from the company’s previous close.

Several other brokerages have also recently issued reports on ABT. Raymond James Financial lowered their target price on shares of Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating on the stock in a research note on Friday. The Goldman Sachs Group lowered their price target on shares of Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating on the stock in a research report on Friday. Oppenheimer decreased their target price on shares of Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating on the stock in a research note on Friday. Wells Fargo & Company increased their price target on Abbott Laboratories from $142.00 to $146.00 and gave the company an “overweight” rating in a report on Thursday, October 16th. Finally, Evercore ISI reduced their price objective on Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a research report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, Abbott Laboratories currently has an average rating of “Moderate Buy” and an average target price of $140.79.

Abbott Laboratories Price Performance

ABT stock traded down $1.44 during trading on Friday, hitting $107.17. The stock had a trading volume of 13,962,425 shares, compared to its average volume of 9,736,540. Abbott Laboratories has a twelve month low of $105.78 and a twelve month high of $141.23. The company’s 50-day moving average price is $125.23 and its two-hundred day moving average price is $128.54. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.70 and a quick ratio of 1.24. The stock has a market capitalization of $186.36 billion, a P/E ratio of 13.44, a PEG ratio of 2.00 and a beta of 0.72.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting analysts’ consensus estimates of $1.50. The business had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. Abbott Laboratories had a return on equity of 17.60% and a net margin of 31.88%.The business’s revenue was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, research analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Institutional Trading of Abbott Laboratories

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ABT. IMG Wealth Management Inc. grew its position in Abbott Laboratories by 759.1% in the 2nd quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock valued at $26,000 after acquiring an additional 167 shares in the last quarter. Harbor Capital Advisors Inc. purchased a new stake in shares of Abbott Laboratories during the fourth quarter worth $27,000. Cloud Capital Management LLC acquired a new stake in shares of Abbott Laboratories in the third quarter valued at $29,000. Guerra Advisors Inc purchased a new position in Abbott Laboratories in the third quarter valued at $31,000. Finally, Anfield Capital Management LLC grew its position in shares of Abbott Laboratories by 81.3% during the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock worth $32,000 after buying an additional 104 shares in the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Underlying business strength: Med‑tech (devices) and established pharmaceuticals posted solid double‑digit growth, adjusted EPS grew year‑over‑year and management reiterated multi‑year organic sales and EPS growth targets — factors that support the company’s long‑term cash generation and dividend profile. Abbott Reports Fourth‑Quarter and Full‑Year 2025 Results; Issues 2026 Financial Outlook
• Positive Sentiment: Value/buy thesis emerges after the pullback: commentators and some retail/institutional analysts view the selloff as a buying opportunity given the company’s Dividend King status, scope for share buybacks, and upside to longer‑term targets. Is Abbott’s January Pullback a Good Time to Buy?
• Neutral Sentiment: Mixed Q4 results: Adjusted EPS matched Street expectations (about $1.50) and revenue rose ~4.4% year‑over‑year, but top‑line fell short of consensus — a mixed beat/miss that leaves fundamentals intact but removes near‑term upside. Abbott Laboratories Q4 2025 earnings call transcript
• Negative Sentiment: Revenue miss driven by Nutrition and Diagnostics: Nutrition sales contracted (near‑9% decline) as higher retail prices reduced demand and commodity costs remained elevated; diagnostics also weakened as COVID‑related testing continued to normalize — these segmental weaknesses pressured the quarter. ABT Q4 deep dive: Nutrition weakness and innovation shape 2026 outlook
• Negative Sentiment: Analysts trimmed price targets and adjusted expectations after the revenue miss and guarded guidance — multiple firms cut targets (Sanford Bernstein, Raymond James, Goldman, Piper, etc.), which amplifies downward pressure even when ratings were largely maintained. Abbott Laboratories Analyst Cuts Price Target After Q4 Miss, Expects Sales Growth To Accelerate In H2
• Negative Sentiment: Bears hedging/increased downside bets: Unusual options activity (large spike in put buying) suggests traders are positioning for further near‑term weakness, which can amplify volatility.
• Negative Sentiment: Regulatory/integrity risk: Indian authorities are scrutinizing a codeine‑based cough syrup supplied by Abbott’s local unit — a reputational/regulatory overhang that could create incremental uncertainty in certain markets. Abbott faces India scrutiny in cough syrup abuse investigation, documents show

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.